Kiromic BioPharma, Inc. (NASDAQ:KRBP – Get Free Report) fell 2.7% during mid-day trading on Thursday . The stock traded as low as $0.90 and last traded at $0.90. 340 shares changed hands during trading, a decline of 93% from the average session volume of 4,613 shares. The stock had previously closed at $0.93.
Kiromic BioPharma Stock Up 2.8 %
The stock’s fifty day simple moving average is $0.99 and its 200 day simple moving average is $1.50. The firm has a market capitalization of $1.42 million, a PE ratio of -0.14 and a beta of 1.84.
Kiromic BioPharma Company Profile
Kiromic BioPharma, Inc, a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1.
Recommended Stories
- Five stocks we like better than Kiromic BioPharma
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Nebius Group: The Rising Star in AI Infrastructure
- Expert Stock Trading Psychology Tips
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for Kiromic BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiromic BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
